首页> 外国专利> Method for predicting therapeutic effect on colorectal cancer patients with enhanced expression of TK1 protein

Method for predicting therapeutic effect on colorectal cancer patients with enhanced expression of TK1 protein

机译:TK1蛋白表达增强对大肠癌患者疗效的预测方法

摘要

The present invention provides a method for predicting the therapeutic effect of chemotherapy using an antitumor agent containing trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5 on a colorectal cancer patient, the method comprising the following steps (1) to (3). As the means for solving the problem, the following invention is provided: a method comprising (1) detecting the expression of TK1 protein by an immunohistochemical method in tumor cells contained in a biological sample obtained from the patient; (2) based on the detection results obtained in step (1), classifying the tumor cells into positive cells and negative cells, and calculating the percentage of positive cells in the tumor cells; and (3) based on the calculation results obtained in step (2), predicting that when the percentage is 30% or more, the patient is likely to sufficiently respond to chemotherapy using the antitumor agent containing trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5.
机译:本发明提供了使用摩尔比为1∶0.5的含有三氟吡啶和盐酸替吡西酯的抗肿瘤药对大肠癌患者的化疗的治疗效果的预测方法,该方法包括以下步骤(1)〜(3)。作为解决问题的手段,提供以下的发明:一种方法,其包括:(1)通过免疫组织化学方法检测在从患者获得的生物样品中包含的肿瘤细胞中TK1蛋白的表达; (2)根据步骤(1)中获得的检测结果,将肿瘤细胞分为阳性细胞和阴性细胞,并计算阳性细胞在肿瘤细胞中的百分比; (3)根据步骤(2)中获得的计算结果,预测当百分比为30%或更高时,患者可能使用摩尔比为3的含有三氟吡啶和盐酸替吡西酯的抗肿瘤药对化疗有足够的反应。 1:0.5。

著录项

  • 公开/公告号JP6312660B2

    专利类型

  • 公开/公告日2018-04-18

    原文格式PDF

  • 申请/专利权人 大鵬薬品工業株式会社;

    申请/专利号JP20150517145

  • 发明设计人 坂本 一樹;伊藤 雅信;

    申请日2014-05-16

  • 分类号G01N33/574;G01N33/48;G01N33/53;

  • 国家 JP

  • 入库时间 2022-08-21 13:08:37

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号